GLAND

Gland Pharma Limited

Complex generic injectables and sterile products, difficult-to-manufacture dosage forms

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

glandpharma.com

Ask AI

Key metrics

Price as of 2026-10-16

Stock price

₹3043.40

Market cap

50,163 Cr

Stock P/E

44.4

P/B

4.84

Dividend yield

0.6%

ROE (FY26)

9.9%

ROCE (FY26)

14.1%

Operating margin (FY26)

18.8%

Debt / equity (FY26)

0.02

OCF / EBITDA (FY26)

63.3%

OCF / EBITDA (3Y)

69.5%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Gland Pharma makes generic injectable medicines and active pharmaceutical ingredients (APIs) for pharmaceutical companies in the United States, Europe, India and other markets, both under its own approvals and as a contract development and manufacturing (CDMO) partner.

Company snapshot

15thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives

✓Net margin of 16.0% — the business keeps a healthy share of every rupee it earns.

2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

Metric	Sept 2023	Dec 2023	Mar 2024	Jun 2024	Sept 2024	Dec 2024	Mar 2025	Jun 2025	Sept 2025	Dec 2025	Mar 2026	Jun 2026
Sales	1,373 Cr	1,545 Cr	1,537 Cr	1,402 Cr	1,406 Cr	1,384 Cr	1,425 Cr	1,506 Cr	1,487 Cr	1,695 Cr	1,743 Cr	1,800 Cr
Operating expenses (approx.)	1,049 Cr	1,189 Cr	1,179 Cr	1,137 Cr	1,109 Cr	1,024 Cr	1,077 Cr	1,138 Cr	1,173 Cr	1,260 Cr	1,230 Cr	1,311 Cr
EBITDA	324 Cr	356 Cr	359 Cr	264 Cr	297 Cr	360 Cr	348 Cr	368 Cr	314 Cr	435 Cr	513 Cr	489 Cr
OPM %	23.6%	23.1%	23.3%	18.9%	21.1%	26.0%	24.4%	24.4%	21.1%	25.7%	29.4%	27.2%
Other income	53 Cr	37 Cr	42 Cr	51 Cr	60 Cr	58 Cr	44 Cr	58 Cr	84 Cr	63 Cr	111 Cr	61 Cr
Interest	6 Cr	5 Cr	10 Cr	6 Cr	6 Cr	23 Cr	7 Cr	11 Cr	8 Cr	4 Cr	10 Cr	4 Cr
Depreciation	81 Cr	105 Cr	93 Cr	92 Cr	94 Cr	96 Cr	96 Cr	101 Cr	106 Cr	108 Cr	109 Cr	111 Cr
Profit before tax	290 Cr	283 Cr	298 Cr	218 Cr	257 Cr	299 Cr	288 Cr	313 Cr	284 Cr	362 Cr	506 Cr	435 Cr
Tax %	33.0%	32.2%	35.5%	34.1%	36.3%	31.6%	35.3%	31.1%	35.3%	27.8%	27.5%	27.1%
Net profit	194 Cr	192 Cr	192 Cr	144 Cr	164 Cr	205 Cr	187 Cr	215 Cr	184 Cr	261 Cr	367 Cr	317 Cr
EPS (₹)	₹11.78	₹11.65	₹11.68	₹8.73	₹9.93	₹12.42	₹11.32	₹13.08	₹11.15	₹15.87	₹22.26	₹19.23

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

Metric	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	3,463 Cr	4,401 Cr	3,625 Cr	5,665 Cr	5,617 Cr	6,431 Cr	Sign in free for the trailing twelve months
Operating expenses (approx.)	2,161 Cr	2,891 Cr	2,600 Cr	4,332 Cr	4,348 Cr	4,801 Cr	Sign in free for the trailing twelve months
EBITDA	1,302 Cr	1,510 Cr	1,025 Cr	1,333 Cr	1,269 Cr	1,630 Cr	Sign in free for the trailing twelve months
OPM %	37.6%	34.3%	28.3%	23.5%	22.6%	25.3%	Sign in free for the trailing twelve months
Other income	135 Cr	224 Cr	240 Cr	170 Cr	214 Cr	316 Cr	Sign in free for the trailing twelve months
Interest	3 Cr	5 Cr	7 Cr	26 Cr	42 Cr	33 Cr	Sign in free for the trailing twelve months
Depreciation	99 Cr	110 Cr	147 Cr	345 Cr	378 Cr	424 Cr	Sign in free for the trailing twelve months
Profit before tax	1,335 Cr	1,619 Cr	1,055 Cr	1,133 Cr	1,063 Cr	1,465 Cr	Sign in free for the trailing twelve months
Tax %	25.3%	25.1%	25.9%	31.8%	34.3%	29.9%	Sign in free for the trailing twelve months
Net profit	997 Cr	1,212 Cr	781 Cr	772 Cr	699 Cr	1,027 Cr	Sign in free for the trailing twelve months
EPS (₹)	₹63.07	₹73.81	₹47.44	₹46.90	₹42.40	₹62.35	Sign in free for the trailing twelve months
Dividend payout %	0.0%	0.0%	0.0%	0.0%	47.2%	28.9%	Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

Metric	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	16 Cr	16 Cr	16 Cr	16 Cr	16 Cr	16 Cr
Reserves	5,887 Cr	7,141 Cr	7,942 Cr	8,707 Cr	9,134 Cr	10,341 Cr
Borrowings	4 Cr	4 Cr	4 Cr	320 Cr	269 Cr	243 Cr
Other liabilities	589 Cr	672 Cr	815 Cr	1,618 Cr	1,805 Cr	1,910 Cr
Total liabilities	6,496 Cr	7,834 Cr	8,778 Cr	10,661 Cr	11,225 Cr	12,511 Cr
Fixed assets (net)	953 Cr	1,499 Cr	1,559 Cr	3,541 Cr	3,751 Cr	4,052 Cr
CWIP	338 Cr	181 Cr	177 Cr	238 Cr	151 Cr	342 Cr
Investments	0 Cr	155 Cr	0 Cr	0 Cr	0 Cr	0 Cr
Loans & advances	0.25 Cr	0.47 Cr	0.14 Cr	0 Cr	0 Cr	0 Cr
Inventories	1,275 Cr	1,186 Cr	1,945 Cr	1,655 Cr	1,685 Cr	1,744 Cr
Trade receivables	671 Cr	1,199 Cr	871 Cr	1,559 Cr	1,517 Cr	1,891 Cr
Cash & bank	492 Cr	319 Cr	1,909 Cr	357 Cr	2,556 Cr	3,359 Cr
Other assets	2,766 Cr	3,295 Cr	2,316 Cr	3,311 Cr	1,566 Cr	1,122 Cr
Total assets	6,496 Cr	7,834 Cr	8,778 Cr	10,661 Cr	11,225 Cr	12,511 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

Metric	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	605 Cr	791 Cr	364 Cr	997 Cr	915 Cr	1,031 Cr
Cash from investing	-1,524 Cr	-1,003 Cr	1,208 Cr	-1,757 Cr	1,705 Cr	138 Cr
Cash from financing	1,238 Cr	35 Cr	15 Cr	-799 Cr	-433 Cr	-417 Cr
Net cash flow	323 Cr	-174 Cr	1,590 Cr	-1,552 Cr	2,199 Cr	803 Cr
Free cash flow (OCF − Capex)	376 Cr	269 Cr	141 Cr	599 Cr	521 Cr	537 Cr

Ratios

Metric	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROCE %	22.7%	22.7%	13.3%	12.8%	11.7%	14.1%
ROE %	16.9%	16.9%	9.8%	8.9%	7.6%	9.9%
Debtor days	71	99	88	100	98	107
Inventory days	265	211	412	299	311	283
Days payable	83	82	125	156	151	136
Cash conversion cycle	253	228	375	243	258	255
OCF / EBITDA %	46.5%	52.4%	35.5%	74.8%	72.1%	63.3%
OCF / EBITDA % (3 years)	—	—	45.9%	55.6%	62.7%	69.5%
Debt / equity	0.0007	0.0005	0.0005	0.04	0.03	0.02
Current ratio	10.00	10.05	9.46	4.04	4.33	4.68
Net debt / EBITDA	-0.38	-0.21	-1.86	-0.03	-1.80	-1.91